Topic:

Sales and Marketing

Latest Headlines

Latest Headlines

Big Pharma, Google wants you to go viral on YouTube

The champions of digital marketing pounded their chests in dismay earlier this month, when 2013 DTC-spending stats showed online ads on the wane. Down by 14%, and the numbers were pretty paltry to begin with. No wonder, then, that Google is lobbying the pharma business on YouTube's behalf.

Docs that just say no to drug samples slash brand prescribing big-time, study finds

A new  JAMA Dermatology  study shows a huge difference in brand-name scripts written by physicians who turn down drug samples--a 62-percentage-point difference, to be exact.

The price is right for patient-switching on Biogen's new hemophilia med Alprolix

With a pair of long-acting hemophilia meds on the way, Biogen Idec appears poised to shake up the market for the bleeding disease. And though recently approved Alprolix has yet to launch, it has already made waves: Biogen has priced it on par with older therapies, leaving competitors vulnerable to patient-switching.

England sets aside $31M to fund Sovaldi for sickest patients

While next-gen hep C treatment Sovaldi costs $84,000 per 12-week course of treatment, it boasts a 90% cure rate--and that's convinced the U.K.'s National Health Service to spend £18.7 million to fund the treatment for England's sickest patients.

Under fire from local pharmas, China backs off price caps

On Tuesday, the Chinese government quietly announced that it is easing up on its policy of restricting drug prices and will allow pharmaceutical companies to set prices on some medicines, according to Reuters.

Novartis' gain is consumers' $900M loss from stalled Ranbaxy generics

The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis. Not so much for consumers.

New attention disorder could equal a big new ADHD drug market. But is it legit?

There could be a new attention disorder on the block in the future--one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.

Second drug spending report predicts double-digit increases coming

In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes from the second pharmacy benefits management report to be released in three days, this one from CVS Caremark following Express Scripts' missive on Tuesday.

French watchdogs raid Novartis, Roche in Lucentis antitrust probe

The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.

Express Scripts adds fuel to the fire in fight over Gilead Sciences' Sovaldi

Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.